about
sameAs
Rivastigmine for dementia in people with Down syndromeRivastigmine for Alzheimer's diseaseRivastigmine for Alzheimer's diseasePharmacological interventions for unilateral spatial neglect after strokeHuperzine A for mild cognitive impairmentRivastigmine for Alzheimer's diseaseCholinesterase inhibitors for deliriumHuperzine A for Alzheimer's diseaseHuperzine A for Alzheimer's diseaseCurrent pharmacologic options for patients with Alzheimer's diseaseMulti-Target Directed Donepezil-Like Ligands for Alzheimer's DiseaseCholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.Therapy for Alzheimer's Disease: How Effective are Current Treatments?Prescribing patterns for Alzheimer disease: survey of Canadian family physicians.D-cycloserine for Alzheimer's disease.Role of cholinesterase inhibitors in dementia care needs rethinking.A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease.Therapeutic approaches to age-associated neurocognitive disordersPositron emission tomography scans obtained for the evaluation of cognitive dysfunction.Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes.Positive allosteric modulator of α7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates.Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model.Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease.Present and prospective clinical therapeutic regimens for Alzheimer's disease.Errorless learning and spaced retrieval techniques to relearn instrumental activities of daily living in mild Alzheimer's disease: A case report study.A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Progress update: Pharmacological treatment of Alzheimer's disease.Relative tolerability of Alzheimer's disease treatmentsTacrine, Trolox and Tryptoline as Lead Compounds for the Design and Synthesis of Multi-target Agents for Alzheimer's Disease Therapy.Dihydromyricetin ameliorates behavioral deficits and reverses neuropathology of transgenic mouse models of Alzheimer's disease.Treatment of Alzheimer's disease in Brazil: II. Behavioral and psychological symptoms of dementia.Open Science Meets Stem Cells: A New Drug Discovery Approach for Neurodegenerative Disorders.Current Perspectives regarding Stem Cell-Based Therapy for Alzheimer's Disease.Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review
P2860
Q22252965-E185EA4E-2703-4E4C-BA55-320FDFCFE069Q24186551-7B5F35E4-4B81-4754-893D-FC6367FE3A44Q24187067-D16BB55B-0A14-4BDB-BA2A-5F3A583E7BF6Q24187915-3AA1771B-4705-4D65-98BD-EF7A13E2AFADQ24234330-8002BBBC-CC68-466A-886A-204FD33DEBEEQ24241686-073C0A92-8CFC-4773-9C2C-1C0FB0994EC8Q24242314-D0C60AE9-B527-431B-94D7-348715B7AD93Q24243171-3F0FA3B1-7183-49EC-A924-D9F94D940B59Q24245024-DF69954A-F8AC-486D-BEC4-6C7060B9DFC5Q24800530-10580F27-6364-4DB1-A281-8FD9E86DC815Q26744105-59A623B6-1472-4B90-90A9-D659AC06D7B9Q33912750-E6BF9946-AE33-44A7-B2E3-81043FFF226CQ34409349-8CB2472C-D4B0-417B-A141-C8D5C21D98BFQ34683821-F4FF7674-CEA1-40B8-A381-9747C12559F6Q34699222-CA051827-7609-4F93-B196-D1307AE8408EQ35013400-6BAF9DD4-BD8E-4806-97FF-5274847DF1FEQ35236228-032FB487-8595-461E-89E5-AB6E70DCEA71Q35236387-D2F7A460-1A62-4078-B738-0CF7EB39751DQ35446894-6E88BD66-2042-4387-BD63-96F1CE690B7FQ35876403-97FA7ECC-5842-46E5-B980-37E336867476Q36582006-1C7A9DCA-9A79-4974-87EC-F62DA03B66CAQ36678091-554A75FF-BEA8-4E78-B8F3-93C46D29F5C4Q36842150-C3159178-AFA5-46ED-9740-EF087A4398CBQ36876447-6618E96C-1B93-471F-85A9-D7ED1DCA842FQ37062581-31CF0E05-94FF-4FEA-A78E-8E8FB25CBDC1Q37070395-19A1F690-CE38-4439-BB5A-1E2E7EBC40D2Q37129735-AA15EC12-9FDC-4DEC-91F7-60013711B4ADQ37225818-FFD6F5B6-0FF3-480F-8858-B933F6D1477EQ42289492-FA243AE3-13C2-42D5-AFF7-B589A03BA6F2Q43427045-50BAA4E3-A69D-4307-93DE-DF03BE101C12Q47141950-81E9FF37-A3C9-4FAE-8D0B-BF39A2725D58Q50105039-964488DE-02C4-4A99-86E1-614F277A4A80Q52568314-70C60338-AEBB-41D6-A86B-35BCF2899F28Q58698874-63832E86-D3D4-49C2-B20C-B0307D639AC2
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Rivastigmine for Alzheimer's disease
@nl
Rivastigmine for Alzheimer's disease.
@ast
Rivastigmine for Alzheimer's disease.
@en
type
label
Rivastigmine for Alzheimer's disease
@nl
Rivastigmine for Alzheimer's disease.
@ast
Rivastigmine for Alzheimer's disease.
@en
altLabel
Rivastigmine for Alzheimer's disease
@en
prefLabel
Rivastigmine for Alzheimer's disease
@nl
Rivastigmine for Alzheimer's disease.
@ast
Rivastigmine for Alzheimer's disease.
@en
P2093
P2860
P1476
Rivastigmine for Alzheimer's disease
@en
Rivastigmine for Alzheimer's disease.
@en
P2093
Grimley Evans J
V Iakovidou
P2860
P304
P356
10.1002/14651858.CD001191
P407
P577
2000-01-01T00:00:00Z